MARK2 and diabetic kidney disease: Receptor interacting protein kinase‐3 (RIPK3), a serine/threonine kinase, is known to induce necroptosis, a form of programmed cell death that involves phosphorylation of mixed lineage kinase domain like ‌‌(MLKL).[11, 12] Recent studies have shown that RIPK3 expression is upregulated in the podocytes of DKD patients and high glucose (HG) was shown to increase RIPK3 expression in podocytes in vitro.[13, 14] However, these studies have not confirmed whether specific inhibition of podocyte RIPK3 can alleviate DKD in vivo.